The purpose of breast cancer screening is to save lives. To have confidence that the national programme can achieve this aim it must be shown firstly that mortality reductions have been conclusively demonstrated in a relevant pilot study and secondly that these benefits can be reproduced in everyday practice.
EVIDENCE OF MORTALITY REDUCTION
The Forrest report [1] was released when the encouraging results of the Health Insurance Plan (HIP) [2] and Swedish Two Counties Trials [3] were known but since then three randomised trials have failed to show a benefit after screening [4, 5, 6] , The seminal HIP trial suggested mortality reductions but this study is not fully relevant to the UK in 1989. About two-thirds of cancers were detected by clinical examination but the UK programme will rely on mammography alone. The HIP trial employed clinical examination and mammography every year?we shall only be screening triennially. The risk rates of non-attenders in the different populations may also be a reason why the HIP results would overestimate benefits in the UK. The HIP authors concluded that "women with a higher risk of breast cancer tend to self-select themselves for screening" [2] , whereas the UK trial experience was the opposite: "women at high risk of breast cancer tend to be non-participants" [4] , It seems that the same screening activity in different countries may produce different results. Another factor to be borne in mind when considering results from the USA is the threshold for biopsy of screen detected lesions. Benign to malignant ratios of 10:1 have been considered acceptable [7] , even optimal [8] , in America, but the Forrest Report states that a ratio of up to 3:1 should be aimed for [1] .
Several case control studies have been performed in Holland [9, 10] and Italy [11] [26] . During the first screening round in the Swedish Two Counties trial demands on inpatient services increased by at least 150% [27] [29] . The UKTEDBC and Malmo trials have shown that screening for breast cancer does not reduce mortality from the disease with acceptable consistency. Screening centres around the country cannot reasonably be expected to improve on these results and match the standards reached by the world centres of excellence involved in the Swedish Two Counties study. Every effort must be made to decrease the suffering and death caused by breast cancer in this country but unfortunately the epidemiological evidence suggests that screening will not achieve this. The costs both to well women and the NHS along the way are likely to be considerable?perhaps it is time for a rethink [30] .
